Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imiglitazar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 16/20 | 1.00 |
| ▸ | PPARA known ✓ | Q07869 | 14/20 | 1.00 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.69 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imiglitazar SCHEMBL4057640 | 1.00 | PPARG (1.00) | PPARGPPARAFFAR1PPARDKDR | |
| Imiglitazar SCHEMBL440905 | 1.00 | PPARG (1.00) | PPARGPPARAFFAR1PPARDKDR | |
| SCHEMBL6159699 | 0.95 | PPARG (0.90) | PPARGPPARAFFAR1PPARD | |
| SCHEMBL7823357 | 0.95 | PPARG (0.90) | PPARGPPARAFFAR1PPARD | |
| SCHEMBL6160402 | 0.95 | PPARG (0.90) | PPARGPPARAFFAR1PPARDKDR | |
| SCHEMBL6159690 | 0.95 | PPARG (0.90) | PPARGPPARAFFAR1PPARD | |
| SCHEMBL6160399 | 0.95 | PPARG (0.90) | PPARGPPARAFFAR1PPARDKDR | |
| SCHEMBL6158370 | 0.95 | PPARG (0.90) | PPARGPPARAFFAR1PPARDKDR | |
| SCHEMBL6159745 | 0.95 | PPARG (0.90) | PPARGPPARAFFAR1PPARDKDR | |
| SCHEMBL6159738 | 0.95 | PPARG (0.90) | PPARGPPARAFFAR1PPARDKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| US-20240117303-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2024-04-11 | — | — | US | claimed |
| WO-2024019800-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-01-25 | — | — | WO | claimed |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | claimed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| US-20080070958-A1 | Therapeutic Agent for Keratoconjunctival Disorder | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-03-20 | — | — | US | claimed |
| US-6777435-B1 | RETINOID-RELATED RECEPTOR FUNCTION REGULATING AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-08-17 | — | — | US | claimed |
| EP-1077957-B1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-08-04 | — | — | EP | claimed |
| EP-1428531-A1 | Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-06-16 | — | — | EP | claimed |
| US-20040077689-A1 | Abc expression promoters | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | claimed |
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | claimed |
| US-20030134884-A1 | Neovascularization inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-17 | — | — | US | claimed |
| EP-1224178-B1 | CRYSTALS OF AN OXYIMINOALKANOIC ACID DERIVATIVE AND THEIR USE AS ANTIDIABETICS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-06-25 | — | — | EP | claimed |
| EP-1304121-A1 | BODY WEIGHT GAIN INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-04-23 | — | — | EP | claimed |
| US-6518435-B1 | Production method, a method of producing a compound represented by the formula (III) production method of oxyimino- alkanoic acid derivatives having an anti-diabetic activity. | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-11 | — | — | US | claimed |
| EP-1277730-A1 | NEOVASCULARIZATION INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-01-22 | — | — | EP | claimed |
| EP-1227081-A1 | PROCESS FOR THE PREPARATION OF OXYIMINOALKANOIC ACID DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2002-07-31 | — | — | EP | claimed |
| EP-1224178-A1 | CRYSTALS OF AN OXYIMINOALKANOIC ACID DERIVATIVE AND THEIR USE AS ANTIDIABETICS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-24 | — | — | EP | claimed |
| US-6251926-B1 | OXYIMINOALKANOIC ACID DERIVATIVES HAVING HYPOGLYCEMIC EFFECT AND HYPOLIPIDEMIC EFFECT, IS USEFUL FOR TREATMENT OF DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE INFLAMMATORY DISEASE AND ARTERIOSCLEROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | claimed |
| WO-2001032637-A1 | CRYSTALS OF AN OXYIMINOALKANOIC ACID DERIVATIVE AND THEIR USE AS ANTIDIABETICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | GPR119, IRS1, CPT1A | PPARG 401/4885PPARA 152/4885FFAR1 53/4885 |
| US-20040077689-A1 | Abc expression promoters | SREBF1, SREBF2, ABCB4 | PPARG 189/4885PPARA 355/4885FFAR1 1498/4885 |
| US-20030134884-A1 | Neovascularization inhibitors | VEGFA, FLT1, FLT4 | PPARG 1641/4885PPARA 1383/4885FFAR1 3421/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | PPARG 567/4885PPARA 787/4885FFAR1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.